TNFRSF18 and neoplasm: Using in vivo experimental models, the administration of a GITR agonist antibody is associated with reduction of intra-tumoural Treg accumulation and potentiation of anti-tumour CD8+ effector T cell function, leading to enhanced anti-tumour effects [162].